close
close

SWIXX BIOPHARMA ENTERS LATIN AMERICA THROUGH STRATEGIC ACQUISITION AND MERGER WITH BIOPAS

Posted on by darion

(Información remitida por la empresa firmante)

  • Plus 220 million dollars in sales, over 300 employees and therapeutic reach in neurology, oncology, immunology, gastroenterology, rare diseases and specialties, the acquisition expands and transforms the reach of Swixx BioPharma
  • The acquisition brings immediate benefits and creates an attractive, comprehensive and multi-continent partner for biopharmaceutical companies
  • The acquisition builds on Swissx BioPharma’s rapid organic growth; the company was recognized as one of Europe fastest growing companies in 2024

BAAR, Switzerland, May 22, 2024 /PRNewswire/ — Swixx BioPharma AG, a global commercial platform dedicated to providing access to innovative medicines worldwide, today announces its strategic expansion into Latin America with the signing of an agreement to acquire 100% of the capital of Pharma Consulting Group SA, which is the holding company of Laboratorios Biopas SA. With its operational headquarters in BogotaColombia, Biopas is one of Latin America leading independent marketing and distribution companies for international biopharmaceutical companies. Biopas is present in 20 countries, including the “Top 5” Latam markets Argentina, Brazil, Chile, Columbia & Mexico. Closing of the transaction is expected after obtaining the appropriate approvals from regulatory authorities, expected in June –July 2024.

This acquisition follows Swissx BioPharma’s entry into the market Near East village region September 2023 and represents another important step towards fulfilling Swixx’s mission to become the partner of choice for biopharmaceutical companies looking for indirect routes to bringing their medicines to market. Thanks to Biopas’ comprehensive Latam continental coverage, Swixx will now be able to provide an attractive offer covering the mid-to-central parts of the country Eastern EuropeCIS/Eurasia, MENA and now Latin America.

The Biopas management team remains at the helm of the combined company in Latam. The Biopas name will be retained for the Latam business, even when Biopas becomes part of the Swixx BioPharma group.

Jean-Michel LespinasseCEO of Swiftx BioPharma, warmly welcomed the Biopas team to the Swixx BioPharma family: “we look forward to working closely with the brilliant, dedicated professionals that Biopas has attracted throughout Latam,” commented Lespinasse. “We will work with passion, with respect for the staff and the entrepreneurial culture of Biopas, to bring the two companies together and thus create something greater than the sum of their parts.”

“Let me also take this opportunity to greet the founders of Biopas, Pascal and Maria Fernanda Forget it, whom I am delighted to announce, will join us in the respective positions of Latama Regional Executive General Manager and Executive Operations Advisor. Forgetters will also become our shareholders, and Pascal will take a role on the Swixx BioPharma board.”

Benoit Chastaing, non-executive board member of Swixx BioPharma and managing partner at Merieux Equity Partners (Swixx investor) delighted that “this is a breakthrough move for Swiftx. In the blink of an eye, we are creating a highly scalable, completely new kind of partner for the global pharmaceutical industry – offering a true one-stop shop with a real presence on three continents. This gives the multinational biopharma company, for the first time, an effective, serious, yet simple (and easy to manage) strategic alternative to a direct presence outside the world’s top 20 markets.”

Forget about PascalCEO and co-founder of Biopascommented: “We are excited to join the Swixx BioPharma group and contribute to the development of a broad and distinctive cross-regional platform. We strongly believe that by joining forces with Swixx, we will be better prepared to fulfill our mission of bringing innovative medicines to the people of Latin America. Both companies have similar missions and business models, and their combination will generate significant value for our partners and our patients. We will continue to deliver effective solutions and unlock access in the region, while cultivating long-term relationships with all Biopas stakeholders.”

About Swixx BioPharma

Swixx BioPharma has wholly owned subsidiaries in Central and Eastern Europe, Greece, Russia and several Eurasian countries including Belarus, Kazakhstan, Uzbekistan, Near East and now Latin America. Swixx BioPharma employs over 1,300 people and sales are likely to exceed one billion euros in 2024. The company is one of the fastest growing, largest, independent, intercontinental trading platforms for the biopharmaceutical industry. Swixx brings together outstanding talent in rare diseases, oncology and hematology, specialties, vaccines and self-medication under one roof. More information about Swixx BioPharma can be found at: www.swixxbiopharma.com.

About the Laboritorios Biopas Group

Biopas is a leading pharmaceutical company on the market Latin America, specializing in licensing, marketing and sales of cutting-edge specialized pharmaceutical products. Our mission is to meet unmet medical needs and facilitate access to innovative medicines. We provide effective solutions to international pharmaceutical companies looking to take advantage of sales opportunities throughout the region. Works throughout the area Latin America thanks to our wholly owned subsidiaries, we hold leading positions in biopharmaceuticals in the field of CNS, immunology, dermatology, gastroenterology, oncology and rare diseases. Our projected sales for 2024 are approx 220 million dollarssupported by a dedicated team of over 300 employees.

Inquiries from investors and partners of Swissx BioPharma:

Jean-Michel LespinasseCEO[email protected]

Stuart SwansonHead of Corporate Development [email protected]

Swiftx BioPharma media inquiries:

Vedrana Sokac Brataljenovic, Director of Public Affairs[email protected], Tel: +385 1 425 6086

Inquiries about Biopas:

Forget about Pascalexecutive regional general manager of Latam [email protected]

Photo – https://mma.prnewswire.com/media/2417969/FT_Statista.jpgLogo – https://mma.prnewswire.com/media/2417970/Swixx_BioPharma_Logo.jpg

View original content: https://www.prnewswire.co.uk/news-releases/swixx-biopharma-expands-to-latin-america-through-a-strategic-acquisition-and-combination-with-biopas-302152039. HTML